Ocular Therapeutix sees high volume trading after more positive Phase III results

5 January 2017
2019_biotech_test_vial_discovery_big

Ocular Therapeutix (Nasdaq: OCUL) will submit a New Drug Application (NDA) to the US Food and Drug Administration for Dextenza (dexamethasone) in the first quarter of 2017.

The US-based biopharmaceutical company is focused on the development of therapies for diseases and conditions of the eye. Dextenza is designed to treat post-surgical ocular inflammation and pain, through a bioresorbable intracanalicular insert that provides drug release to the surface of the eye over a period of several weeks.

The decision to submit the NDA comes on the back of more positive results from a Phase III clinical trial, in which the test group demonstrated superior secondary endpoints at all measured timepoints. The drug has also exhibited a favorable safety profile.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology